drugset / Trial / NCT00370357
SPL7013 Gel - Male Tolerance Study
Phase 1
Completed
36 enrolled
Starpharma Pty Ltd
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to determine if SPL7013 Gel (VivaGel™) is safe when applied topically once a day for seven consecutive days to the shaft and glans of the penis in healthy male volunteers. The study will compare the safety of SPL7013 Gel on the penile epithelium and urethral mucosa to the safety of a placebo gel. The study will also assess the systemic safety of SPL7013 Gel, systemic absorption of the active ingredient of SPL7013 Gel, and the acceptability of the study products to the male volunteers.
Timeline
- Start
- 2006-08
- Primary completion
- 2007-02
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SPL7013 | Other / unclassified | 3 % | Topical |